Drug Profile
JNJ 40929837
Latest Information Update: 18 Aug 2015
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Leukotriene A4 hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 23 Jun 2011 Johnson & Johnson completes a phase II trial for Asthma in United Kingdom & Germany (NCT01241422, EudraCT2010-022437-28)
- 20 Dec 2010 Phase-II clinical trials in Asthma in Germany (PO)
- 20 Dec 2010 Phase-II clinical trials in Asthma in United Kingdom (PO)